Move to topTop
April 09, 2013

TOKYO--April 9, 2013 -- Terumo Corporation announced today that its Terumo Europe NV subsidiary has signed an exclusive, long-term distribution agreement with BSD Medical Corporation for its MicroThermX® Microwave Ablation System (MicroThermX®). Under the terms of the distribution agreement, Terumo Europe NV will have the exclusive rights to market MicroThermX® in countries in Europe, Western Asia, and Northern Africa.

Through the sale and promotion of a high quality line of devices used for tumor embolization, the closing or blocking of blood vessels, Terumo Europe NV has established itself in the last several years as a pioneer in the field of interventional oncology in Europe, marketing bland beads and drug eluting beads. Embolization, Trans Arterial Chemo Embolization (TACE) and ablation are "hand-in-hand" clinical cathlab-based procedures for the treatment of cancerous tumors and, when used together, provide a less invasive course of treatment to patients. This agreement therefore creates an ideal product synergy with BSD's MicroThermX® product line and enables Terumo Europe NV to offer interventional radiologists and oncologists a complete and compelling therapy solution for the treatment of cancerous tumors.

About the MicroThermX® Microwave Ablation System

The MicroThermX® is a compact, mobile, state-of-the-art, proprietary system that includes a microwave generator, single-patient-use disposable antennas, and a thermistor-based temperature monitoring system. The innovative design of the MicroThermX® is the first of its kind that allows delivery of higher power levels using a single generator. The MicroThermX® utilizes innovative synchronous phased array technology that was developed and patented by BSD to provide larger and more uniform zones of ablation during a single procedure. The MicroThermX® introduces into the Company's product line innovative, high-end disposables - SynchroWave antennas.

About BSD Medical Corporation

BSD Medical Corporation develops, manufactures, markets and services systems to treat cancer and benign diseases using heat therapy, which is delivered using focused radiofrequency (RF) and microwave energy. BSD's product lines include both hyperthermia and ablation treatment systems. The Company has developed extensive intellectual property, multiple products in the market and established distribution in the United States, Europe and Asia. Certain of the Company's products have received regulatory approvals and clearances in the United States, Europe and China. For further information visit BSD Medical's website at www.BSDMedical.com.

About Terumo

Terumo (TSE: 4543) is a global leader in medical technology and has been committed to “Contributing to Society through Healthcare” for 100 years. Based in Tokyo and operating globally, Terumo employs more than 28,000 associates worldwide to provide innovative medical solutions in more than 160 countries and regions. The company started as a Japanese thermometer manufacturer, and has been supporting healthcare ever since. Now, its extensive business portfolio ranges from vascular intervention and cardio-surgical solutions, blood transfusion and cell therapy technology, to medical products essential for daily clinical practice such as transfusion systems, diabetes care, and peritoneal dialysis treatments. Terumo will further strive to be of value to patients, medical professionals, and society at large.

Among the information that Terumo discloses, the forward-looking statements including financial projections are based upon our assumptions using information available to us at the time and are not intended to be guarantees of future events or performance. Accordingly, it should be noted that actual results may differ from those forecasts or projections due to various factors. Factors affecting to actual results include, but are not limited to, changes in economic conditions surrounding Terumo, fluctuations of foreign exchange rates, and state of competition.

 

Information about products (including products currently in development) included in this material is not intended to constitute an advertisement or medical advice.